Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future.
作者信息
Wakuda Kazushige
机构信息
Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Suntou-gun, Shizuoka, Japan.
出版信息
Transl Lung Cancer Res. 2020 Apr;9(2):172-179. doi: 10.21037/tlcr.2020.03.10.
Abstract
摘要
相似文献
1
Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future.复发性小细胞肺癌患者的治疗策略：过去、现在与未来
Transl Lung Cancer Res. 2020 Apr;9(2):172-179. doi: 10.21037/tlcr.2020.03.10.
2
Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review.纳武利尤单抗单药治疗复发小细胞肺癌：回顾性分析与综述。
Anticancer Res. 2020 Mar;40(3):1579-1585. doi: 10.21873/anticanres.14105.
3
Second-line chemotherapy for relapsed small cell lung cancer.
Jpn J Clin Oncol. 1997 Jun;27(3):166-9. doi: 10.1093/jjco/27.3.166.
4
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.铂类双联化疗二线治疗复发性小细胞肺癌患者的系统评价和荟萃分析。
Lung Cancer. 2021 Jun;156:59-67. doi: 10.1016/j.lungcan.2021.04.013. Epub 2021 Apr 19.
5
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.一项关于氨柔比星和拓扑替康联合治疗复发或广泛期小细胞肺癌患者的 II 期研究：冈山西肺癌研究组试验 0401。
Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18.
6
Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.复发转移性与初发性转移性非小细胞肺癌的临床特征和结局比较。
Am J Clin Oncol. 2019 Jan;42(1):75-81. doi: 10.1097/COC.0000000000000483.
7
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.基于 JCOG0605 试验的敏感复发小细胞肺癌的成本效果分析。
Clin Transl Oncol. 2018 Jun;20(6):768-774. doi: 10.1007/s12094-017-1787-y. Epub 2017 Nov 2.
8
Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure.拓扑替康单药治疗阿柔比星单药治疗失败后的复发性小细胞肺癌的疗效评估。
J Rural Med. 2021 Oct;16(4):250-255. doi: 10.2185/jrm.2021-014. Epub 2021 Oct 1.
9
[Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].[利用二代测序检测表皮生长因子受体-酪氨酸激酶抑制剂复发的非小细胞肺癌患者循环肿瘤DNA并分析耐药机制]
Zhonghua Bing Li Xue Za Zhi. 2018 Dec 8;47(12):904-909. doi: 10.3760/cma.j.issn.0529-5807.2018.12.002.
10
Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.一名复发性肺腺癌患者出现与纳武利尤单抗相关的严重血小板减少症：病例报告及文献复习
J Med Case Rep. 2019 Oct 24;13(1):316. doi: 10.1186/s13256-019-2245-y.
引用本文的文献
1
Influencing factors of efficacy and long-term use of amrubicin in patients with small cell lung cancer.影响氨柔比星治疗小细胞肺癌患者疗效和长期使用的因素。
Thorac Cancer. 2023 May;14(14):1286-1293. doi: 10.1111/1759-7714.14871. Epub 2023 Mar 30.
本文引用的文献
1
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.纳武利尤单抗单药治疗和纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌：CheckMate 032 随机队列研究结果。
J Thorac Oncol. 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004. Epub 2019 Oct 17.
2
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.在 DLL3 表达、复发/难治性小细胞肺癌的三线及以上患者中，罗瓦匹妥珠单抗特西利单抗的疗效和安全性：来自 II 期 TRINITY 研究的结果。
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966. doi: 10.1158/1078-0432.CCR-19-1133. Epub 2019 Sep 10.
3
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.帕博利珠单抗联合紫杉醇治疗复发或难治性小细胞肺癌的 II 期研究。
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.
4
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.奥拉帕利联合替莫唑胺治疗复发性小细胞肺癌。
Cancer Discov. 2019 Oct;9(10):1372-1387. doi: 10.1158/2159-8290.CD-19-0582. Epub 2019 Aug 15.
5
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.NCCN 指南解读：小细胞肺癌，2018 年版 2.0
J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.
6
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
7
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.替莫唑胺联合维利帕利或安慰剂治疗复发敏感型或难治性小细胞肺癌的随机、双盲、Ⅱ期研究。
J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15.
8
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.复发难治性小细胞肺癌患者使用二线帕唑帕尼治疗：希腊肿瘤研究小组的一项多中心II期研究
Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.
9
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.小细胞肺癌的化学敏感性复发通过EZH2-SLFN11轴进行。
Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.
10
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.一项关于林西替尼（OSI-906）与拓扑替康对比治疗复发小细胞肺癌患者的随机II期研究。
Oncologist. 2016 Oct;21(10):1163-1164. doi: 10.1634/theoncologist.2016-0220. Epub 2016 Sep 30.
Zotero 插件